Subjects With Advanced or Metastatic Solid Tumor Malignancies
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, Phase 1, multicenter, continuous dose escalation study of
XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies.
The study will consist of 4 periods:
Screening Period (up to 28 days prior to Cycle 1 Day 1) Safety Run-in Period (Cycle 1;
continuous dosing on Days 1-21 of 28-day cycle) Continuous Dosing Period (Cycle 2 and beyond;
continuous dosing on Days 1-28 of 28-day cycle) Safety Follow-up Period (30 days post-last
dose).